NUVL vs. KDNY, PRAX, IGMS, OCGN, VTYX, RPRX, BMRN, BGNE, VTRS, and SRPT
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Chinook Therapeutics (KDNY), Praxis Precision Medicines (PRAX), IGM Biosciences (IGMS), Ocugen (OCGN), Ventyx Biosciences (VTYX), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), Viatris (VTRS), and Sarepta Therapeutics (SRPT).
Chinook Therapeutics (NASDAQ:KDNY) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability.
Chinook Therapeutics has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.
Chinook Therapeutics presently has a consensus price target of $41.00, indicating a potential upside of 1.51%. Nuvalent has a consensus price target of $90.78, indicating a potential upside of 38.34%. Given Chinook Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nuvalent is more favorable than Chinook Therapeutics.
Chinook Therapeutics received 2 more outperform votes than Nuvalent when rated by MarketBeat users. However, 71.43% of users gave Nuvalent an outperform vote while only 50.00% of users gave Chinook Therapeutics an outperform vote.
Nuvalent has lower revenue, but higher earnings than Chinook Therapeutics. Nuvalent is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nuvalent had 7 more articles in the media than Chinook Therapeutics. MarketBeat recorded 7 mentions for Nuvalent and 0 mentions for Chinook Therapeutics. Chinook Therapeutics' average media sentiment score of 1.01 beat Nuvalent's score of 0.67 indicating that Nuvalent is being referred to more favorably in the news media.
Nuvalent has a net margin of 0.00% compared to Nuvalent's net margin of -4,199.93%. Chinook Therapeutics' return on equity of -26.54% beat Nuvalent's return on equity.
95.2% of Chinook Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 16.8% of Chinook Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Nuvalent beats Chinook Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
